It was a busy first six months of 2023 for veterinary professionals and practices, and the rest of the year isn’t likely to slow down. With the tradeshow circuit back to pre-pandemic attendance and new regulations going into effect, veterinary professionals have had to manage far more than just patient care.
With the year a little more than halfway over, we’re taking a quick “paws” to review some of the major changes that have already gone into effect, ones still to come, and ways you can prepare your practice for success in the second half of the year. Here are the top five changes and trends we’re keeping an eye on.
1. Implementation of GFI #256
Earlier this year, the FDA finalized regulatory guidance for compounded medications, known as GFI #256. The new guidance affects both office stock in veterinary practices and individual animal-patient prescriptions. However, it does not include cGMP products from 503B outsourcing facilities, like Epicur Pharma.
Some of the biggest changes that GFI #256 brings include:
- Increased documentation for patient-specific prescriptions
- Limitations to available 503A office-stock drugs
Although veterinary professionals were aware of the impending changes with GFI for months, many have been left scrambling since it went into effect in April. If GFI is affecting your practice’s ability to get compounded medications for office use, partnering with a trusted 503B outsourcing facility can help you eliminate risks of limited ordering.
Because 503B outsourcing facilities aren’t included in the GFI changes, partners like Epicur Pharma can ensure your practice stays stocked with high quality, manufactured medications and help streamline ordering processes with our iFill ordering system. The system lists what you can order for office stock and will provide the documentation necessary for patient-specific orders if the guidance requires it.
Our team is dedicated to helping you stay up to date on regulation changes.
We partner with experts to offer educational webinars that ensure you understand the impact on your practice. Watch our most recent on-demand GFI webinar with Nicole Clausen, What Every Inventory Manager Needs to Know About Compounded Medications.
2. Impending USP Guidelines on Beyond-Use Dates
Coming in late 2023, new USP guidelines will limit Beyond-Use Dates (BUDs) on drugs from 503A compounding pharmacies. The changes will shorten the BUDs of compounded 503A products and will not allow pharmacies to establish longer dates, even with sufficient evidence to support or prove their cause.
The new guidelines will only affect BUDs and not expiration dates because drugs can only be assigned with an expiration date after the completion of extensive testing, which 503Bs are required to follow.
As with GFI, this USP guideline will not affect 503B products because they have longer/proven expiration dates validated by cGMP. This impending change is another reason why having a 503B partner is critical to your practice and patient care.
Want to learn more about Beyond-Use Dates vs Expiration Dates?
Read our blog!
Switching to a 503B partner now will not only alleviate any challenges you’ve had since GFI went into place, but it will also ensure you can order with ease as the impending USP guidelines of BUDs goes into effect!
3. Continued Burnout and Veterinary Staff Shortages
Unemployment rates continue to affect the veterinary industry, with estimates that by 2030 there will be a shortage of 15,000 veterinarians, making the demand for more workers increasingly urgent.
Veterinarians and staff alike struggle to cope with the challenges they face in their daily work environments. As a result, many dedicated professionals are turning away from veterinary medicine, exacerbating the current staff shortages. It is now more important than ever to be aware of the signs and symptoms of burnout so you can properly address them within your work environment.
Although it can be difficult to see, there are some ways you can help find solutions within your practice. It often starts with communication. Make sure you check in with colleagues, notice signs of stress, and offer help. Small changes within your work environment can help relieve the daily non-stop work, like setting a proper lunch break time. You can also automate processes where it makes sense and enhances your practice, such as online ordering and inventory management systems, to give time back to staff.
Need support? Many veterinary professionals are in crisis. Not One More Vet (NOMV) provides the necessary support to all members of veterinary teams and students who are struggling. Contact them today.
4. Prioritizing Client and Patient Relations
In the evolving veterinary industry, prioritizing client and patient relationships remains essential to ensuring the highest possible level of care, especially when transitioning to a service-based model. With this shift, clients often seek a personalized experience knowing you value their pet’s health and well-being as if it were your own.
Did you know?
All Epicur Pharma drugs are ready to ship same business day with 1-2 days in transit. Order today!
Often, veterinary hospital visits can be stressful for both the patient and the client. Creating an environment to keep everyone comfortable and educated throughout the visit can build trust with patients and clients.
Establishing trust with pet owners fosters a positive customer experience and nurtures long-lasting loyalty. This can be achieved by creating opportunities to share your knowledge with clients. Whether it’s tips on proper medication usage and storage, guidance on applying medications, reminders of seasonal factors such as ticks or high heat, sharing your expertise helps build a strong relationship with pet owners. To make the client’s time at your practice convenient, you can also stay regularly stocked on compounded medications approved for dispensing through a 503B outsourcing facility like Epicur Pharma.
5. Product Shortages
Product shortages are inevitable and variable, stemming from product recalls, labor shortages, unavailability of necessary packaging, or active pharmaceutical ingredients (APIs). Recent compounded medication shortages from some suppliers have included Buprenorphine Injection, Tacrolimus AQ, and Gabapentin – leaving offices out of stock and unable to have the necessary medications readily available in case of patient emergencies. Keep in mind that for compounded medication, another supplier will be able to help you. The uncertainty of this makes it especially important to have a veterinary pharmacy that you can rely on to inform you of product changes and availability.
With Epicur, consistent and reliable 503B manufactured products are our standard every time. We offer one of the largest selections of 503B manufactured drugs that are traditionally compounded for animal health among currently registered facilities nationwide, with most of our products not having a backorder or shortage in years!
Partner with a pharmacy you trust—explore our available medications.
More to Read
Beyond the Ulcer: Understanding Equine Gastric Disease with Camilla Jamieson
Expert Veterinary Insights on ESGD, EGGD, and Modern Treatment Approaches Dr. Camilla Jamieson always knew she wanted to be a horse vet. Growing up around horses, she started learning about equine medicine as a kid and her passion for a career in the field was reinforced when a few equine veterinarians took her under their wing. Today, she is an internationally trained equine internal medicine specialist and trusted leader in the field, gaining expertise from her work in demanding equine medical environments all across the globe. We’ve been lucky enough to partner with her for several educational webinars, and now we’ve sat down with her to talk one-on-one about the intricacies of Equine Gastric Ulcer Syndrome (EGUS) and why effective diagnosis and management require more than a one-size-fits-all approach. Watch her September webinar! What are some of the biggest misconceptions about Equine Gastric Ulcer Syndrome you see among horse owners and veterinary professionals? One of the biggest misconceptions is that we can diagnose and treat equine gastric ulcers based on clinical signs alone. Many horses are treated for ulcers because of behavioral changes or performance issues, but those signs can be caused by a wide range of conditions. Without a gastroscopic examination, it can be difficult to determine whether ulcers are truly the underlying problem. Another challenge is that all gastric ulcers are often treated as though they’re the same disease. They’re not. The stomach has two distinct regions, and ulcers in those areas can behave very differently. The glandular and squamous portions of the stomach often require different treatment protocols, treatment durations, and management strategies. When treatment is selected without identifying the type and location of the ulcer, there’s a risk of using the wrong therapy or not treating long enough to achieve meaningful healing. I also encourage veterinarians and owners to think about equine gastric disease as a long-term management condition. In many horses, especially performance horses, it’s not a matter of treating once and never dealing with it again. Managing the underlying risk factors is often just as important as treating the active disease. How has vets’ understanding of EGUS changed since you started in the field, and how has that impacted diagnosis and treatment? Fifteen years ago, most discussions around EGUS centered on acid suppression and oral omeprazole therapy. Today, our understanding is much broader. We know much more about how stress affects gastric health, how feeding practices influence acid production, and how horses’ natural grazing behavior impacts the stomach environment. That expanded understanding has changed how we approach equine gastric disease management. We now recognize that diet, forage availability, stress reduction, turnout, and overall management are critical components of successful long-term care. At the same time, veterinarians have more therapeutic options available, including different proton pump inhibitors and treatment approaches tailored to individual cases. While the fundamentals of diagnosis remain the same, access to gastroscopy has improved significantly. More practitioners have access to endoscopy equipment, making definitive diagnosis of Equine Gastric Ulcer Syndrome more accessible than ever before. How do treatment approaches differ between Equine Squamous Gastric Disease (ESGD) and Equine Glandular Gastric Disease (EGGD)? Understanding the difference between ESGD and EGGD directly impacts treatment selection, expected healing time, client communication, and long-term management. For example, many squamous ulcers respond well to omeprazole and may improve within a few weeks. More severe glandular or pyloric lesions often require much longer treatment periods and significantly different expectations. In those cases, I prepare owners for the possibility of months of therapy rather than weeks. A definitive diagnosis also helps build client confidence and compliance. When owners can see endoscopic images and understand exactly what is being treated, it becomes much easier to explain why a particular treatment plan is necessary, why healing takes time, and why follow-up evaluations may be required. You’ve had experience working with extended-release injectable omeprazole before its introduction in the United States. What first drew your attention to this treatment approach? I went to vet school in England, and the Bova product was already on the market then, so I was aware that it was available. I got hands-on experience with the injectable omeprazole and used it a lot when I worked in the Middle East for four years after my residency. Our medication supply was all Australian products, so we had the Bova products through our Australian supplier. I worked with large stud farms that managed large horse herds, and daily oral medication administration wasn’t always practical. Injectable therapy offered a convenient alternative because multiple horses could be treated on a weekly schedule rather than requiring daily dosing. That convenience factor stood out immediately. Instead of coordinating daily administration, treatments could often be incorporated into routine veterinary visits. While management practices and owner preferences vary considerably from one region to another, injectable therapy provided a valuable option in situations where consistent oral administration was challenging. Based on the research and clinical cases you’ve seen, what types of horses seem to benefit most from injectable omeprazole therapy? I don’t think benefit is necessarily tied to breed or discipline. Instead, it’s often related to management and practicality. Some horses simply aren’t ideal candidates for daily oral medication because of feeding schedules, travel demands, owner availability, or difficulty maintaining fasting protocols. Every case is different. Treatment decisions should be individualized based on the horse, the owner, and the management environment. One of the advantages veterinarians have today is a growing range of therapeutic options that can be matched to the specific needs of each patient. Injectable Omeprazole for Horses See all the benefits of our omeprazole and discover why over 200,000 doses have sold globally! Product Benefits & Advantages What does current research suggest about the role of injectable omeprazole in managing equine glandular gastric disease? One area that continues to generate interest is how different formulations can help address some of the challenges associated with oral therapy. For example, one of the limitations of traditional oral omeprazole is that efficacy can be influenced
Controlled Substances 101: How & Why You Must Comply! Parts 1 and 2
December 8 | 7 p.m. ET RACE-Approved CE Credit Hours: 2Free to attend Attendees will learn how to improve security, prevent theft per DEA regulations and proactively prepare for a DEA audit and best practice time saving suggestions from a previous veterinary practice owner, consultant & public speaker/educator, who has worked with Veterinarians cited by the DEA. Save My Seat
Smooth Delivery: A Novel Extended-Release Buprenorphine for Use in Laboratory Rodents
November 19 | 8 p.m. ET RACE-Approved CE Credit Hours: 1Free to attend Attendees will gain practical insight into how improved flow characteristics enhance both the ease of administration and animal well-being, while ensuring compliance with regulatory and quality standards. In addition, attendees will learn optimal administration techniques and best practices for post-administration monitoring. Save My Seat